Reports
Sale
Tardive Dyskinesia Market Size, Share, Trends, Analysis: By Type: Bradykinesias, Hyperkinesias; By Drug Class: Dopamine-Depleting Medications, VMAT2 inhibitors, GABA Receptor Agonist Medications, Anticholinergic Medications; By End User: Hospital, Clinics; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Tardive Dyskinesia Market Outlook
The tardive dyskinesia market size is expected to grow at a CAGR of 3.2% during the forecast period of 2024-2032, driven by the rising incidence of mood disorders leading to heightened application of antipsychotic medications in patients across the major markets.
Tardive Dyskinesia Market Overview
Tardive dyskinesia is a medical condition characterized by involuntary movements in the body as a side effect of antipsychotic medications, neuroleptic drugs or major tranquilizers commonly used to treat mental problems. The prevalence rate is at least 20 % in all the patients who have encountered first generation neuroleptics as some form of treatment. Middle-aged to senior women are more susceptible to develop the condition as compared to men. Post-menopausal women have a 30% higher incidence rate. It can be broadly categorized into orofacial dyskinesia which leads to uncontrollable movements in the face and dyskinesia of the limbs, affecting arms, legs, toes, and fingers. The most frequently occurring symptoms involve spontaneous movements of mouth and tongue.
Increasing Burden of Mood Disorders
The tardive dyskinesia market demand is driven by the growing prevalence of mental disorders such as schizophrenia, bipolar disorder, major depressive disorder, and schizoaffective disorder. Major depressive disorder is a common psychiatric disorder with an average lifetime prevalence rate of 12% . Globally 46 million people around the world are living with bipolar disorder, out of which 2.8% constitute the United States population. Schizophrenia affects approximately 24 million people worldwide. Therefore, the rising incidence of such conditions has led to increased application of antipsychotic medications, impacting the tardive dyskinesia market significantly.
Rising FDA Approvals for New Drug Formulations to Bolster the Tardive Dyskinesia Market Growth
In September 2023, Neurocrine Biosciences’ valbenazine oral granules called Ingrezza got accepted by the FDA for a New Drug Application (NDA) review. A selective vesicular monoamine transporter 2 (VMAT2) inhibitor, Valbenazine, showed positive results in the analysis of the three studies (KINECT™ 3, KINECT™ 4, and J-KINECT™) wherein the drug administration resulted in sustained and substantial disease improvement in patients. The surge in clinical trials and expediated drug development with the help of the latest technologies is a key driver leading to enhanced tardive dyskinesia market share.
Surge in Research Activities for Improved Treatment Alternatives
The market growth is fueled by the expediated drug development and clinical trials to maintain efficacy and offer quality solutions for patients. Clonazepam , a benzodiazepine with indirect GABA agonist activity, Amantadine, a blocker of N-methyl-D-aspartate glutamate receptors and Tetrabenazine, a selective VMAT2 inhibitor are some key drugs under consideration to be used as an option. Gingko biloba, which acts as an antioxidant, also demonstrated potential efficacy in decreasing symptoms by using brain-derived neurotrophic factor signaling as a plan of action.
Tardive Dyskinesia Market Segmentation
Market Breakup by Type
- Bradykinesias
- Hyperkinesias
Market Breakup by Drug Class
- Dopamine-Depleting Medications
- VMAT2 inhibitors
- GABA Receptor agonist medications
- Anticholinergic Medications
Market Breakup by End User
- Hospital
- Clinics
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Tardive Dyskinesia Market Regional Analysis
Owing to high incidence of mental disorders, the United States has witnessed ample tardive dyskinesia market growth in the historical period. The presence of vital pharmaceutical companies and rising mergers and collaborations amongst them to boost their product portfolio played a critical role in the substantial market share.
With a robust medical and research infrastructure, Europe is also a key market for tardive dyskinesia. Along with a well-structured regulatory framework, the government plays a pivotal role in setting up numerous campaigns to educate the public about mental health disorders and the underlying side effects it may offer.
The Asia Pacific region is expected to witness a growth in the tardive dyskinesia market share, owing to the growth in drug launches. In July 2023, Japan based Mitsubishi Tanabe Pharma Corporation launched REMLEAS as the new tardive dyskinesia treatment drug. The drug has received marketing approval across 3 major ASEAN countries including Thailand, Indonesia, and Singapore. REMLEAS is a vesicular monoamine transporter type 2 inhibitor which reduces dopamine intake to treat the symptoms in patients.
Tardive Dyskinesia Market: Competitor Landscape
In February 2023, Teva Pharmaceuticals received FDA approval for AUSTEDOXR (deutetrabenazine), a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). It is an additional formulation to the currently marketed twice daily formula and is made available in multiple tablet strengths like 6 mg, 12 mg, and 24 mg. It can be administered with or without food as well. The new formula may lead to a decreased pill count in the patients, indicating the rising emphasis on offering convenience to the patients. Innovation and increased research activities in drug development is a major trend adopted by prominent companies across major markets.
The key features of the tardive dyskinesia market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries
- Medicure Inc
- Mylan N.V
- Bionpharma
- Hetero
- Johnson & Johnson Services, Inc.
- Bausch Health
- Sanofi
- GlaxoSmithKline Plc.
- Lupin Pharmaceuticals Inc
- Amgen Inc
- Novartis AG
- Lilly
- Lannett Co Inc
- Neurocrine Biosciences, Inc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Tardive Dyskinesia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Drug
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Tardive Dyskinesia Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Tardive Dyskinesia Forecast (2017-2032)
5.3 EU-4 and United Kingdom Tardive Dyskinesia Epidemiology Forecast (2017-2032)
5.3.1 Germany Tardive Dyskinesia Epidemiology Forecast (2017-2032)
5.3.2 France Tardive Dyskinesia Epidemiology Forecast (2017-2032)
5.3.3 Italy Tardive Dyskinesia Epidemiology Forecast (2017-2032)
5.3.4 Spain Tardive Dyskinesia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Tardive Dyskinesia Epidemiology Forecast (2017-2032)
5.4 Japan Tardive Dyskinesia Epidemiology Forecast (2017-2032)
6 Tardive Dyskinesia Market Overview – Seven Major Markets
6.1 Tardive Dyskinesia Market Historical Value (2017-2023)
6.2 Tardive Dyskinesia Market Forecast Value (2024-2032)
7 Tardive Dyskinesia Market Landscape – Seven Major Markets
7.1 Tardive Dyskinesia diagnostics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Tardive Dyskinesia Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Product Type
8 Tardive Dyskinesia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Tardive Dyskinesia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Tardive Dyskinesia Market Segmentation – Seven Major Markets
11.1 Tardive Dyskinesia Market by Type
11.1.1 Market Overview
11.1.2 Bradykinesias
11.1.3 Hyperkinesias
11.2 Tardive Dyskinesia Market by Drug Class
11.2.1 Market Overview
11.2.2 Dopamine-Depleting Medications
11.2.3 VMAT2 inhibitors
11.2.4 GABA Receptor agonist medications
11.2.5 Anticholinergic Medications
11.3 Tardive Dyskinesia Market by End User
11.3.1 Market Overview
11.3.2 Hospital
11.3.3 Clinics
11.4 Tardive Dyskinesia Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Tardive Dyskinesia Market
12.1 Tardive Dyskinesia Market Historical Value (2017-2023)
12.2 Tardive Dyskinesia Market Forecast Value (2024-2032)
12.3 Tardive Dyskinesia Market by Disease Type
12.4 Tardive Dyskinesia Market by Treatment Type
13 EU-4 and United Kingdom Tardive Dyskinesia Market
13.1 Tardive Dyskinesia Market Historical Value (2017-2023)
13.2 Tardive Dyskinesia Market Forecast Value (2024-2032)
13.3 Germany Tardive Dyskinesia Market Overview
13.3.1 Tardive Dyskinesia Market by Disease Type
13.3.2 Tardive Dyskinesia Market by Treatment Type
13.4 France Tardive Dyskinesia Market Overview
13.4.1 Tardive Dyskinesia Market by Disease Type
13.4.2 Tardive Dyskinesia Market by Treatment Type
13.5 Italy Tardive Dyskinesia Market Overview
13.5.1 Tardive Dyskinesia Market by Disease Type
13.5.2 Tardive Dyskinesia Market by Treatment Type
13.6 Spain Tardive Dyskinesia Market Overview
13.6.1 Tardive Dyskinesia Market by Disease Type
13.6.2 Tardive Dyskinesia Market by Treatment Type
13.7 United Kingdom Tardive Dyskinesia Market Overview
13.7.1 Tardive Dyskinesia Market by Disease Type
13.7.2 Tardive Dyskinesia Market by Treatment Type
14 Japan Tardive Dyskinesia Market
14.1 Tardive Dyskinesia Market Historical Value (2017-2023)
14.2 Tardive Dyskinesia Market Forecast Value (2024-2032)
14.3 Tardive Dyskinesia Market by Disease Type
14.4 Tardive Dyskinesia Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Teva Pharmaceutical Industries
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Medicure Inc
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Mylan N.V
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Bionpharma
21.4.1 Product Portfolio
21.4.2 Demographic Reach and Achievements
21.4.3 Mergers and Acquisitions
21.4.4 Certifications
21.5 Hetero
21.5.1 Product Portfolio
21.5.2 Demographic Reach and Achievements
21.5.3 Mergers and Acquisitions
21.5.4 Certifications
21.6 Johnson & Johnson Services, Inc.
21.6.1 Product Portfolio
21.6.2 Demographic Reach and Achievements
21.6.3 Mergers and Acquisitions
21.6.4 Certifications
21.7 Bausch Health
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Sanofi
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 GlaxoSmithKline Plc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Lupin Pharmaceuticals Inc
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Amgen Inc
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Novartis AG
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Lilly
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Lannett Co Inc
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Neurocrine Biosciences, Inc
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Tardive Dyskinesia Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 3.2% during the forecast period of 2024-2032, driven by the rising incidence of mood disorders.
The market demand is driven increasing prevalence for personalised medicines that addresses the specific symptoms of a patient and offer relevant interventions as per the requirement. The increasing research and development in drug discovery is a major driver.
The increasing research and development in drug discovery and rising FDA approvals is a major market trend. In September 2023, Ingrezza, developed by Neurocrine Biosciences received FDA approval to be treat tardive dyskinesia in patients. In addition, numerous drugs such as Clonazepam, Amantadine and Tetrabenazine are under clinical trials and have shown promising results.
Based on diagnostic types, the market is divided into dopamine-depleting medications, VMAT2 inhibitors, GABA receptor agonist medications and anticholinergic medications.
The types can be categorised into bradykinesias and hyperkinesias.
Major end users in the market include hospitals and clinics.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Teva Pharmaceutical Industries, Medicure Inc., Mylan N.V, Bionpharma, Hetero, Johnson & Johnson Services, Inc., Bausch Health, Sanofi, GlaxoSmithKline Plc., Lupin Pharmaceuticals Inc., Amgen Inc., Novartis AG, Lilly, Lannett Co Inc., and Neurocrine Biosciences, Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER